Seagen Inc.
https://www.seagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seagen Inc.
AZ/Amgen Fail In EU Fast-Track Bid For Tezepelumab
European drug reviewers are not convinced that AstraZeneca and Amgen's investigational treatment for severe asthma, tezepelumab, should be fast-tracked through the EU evaluation system once the companies file for approval.
New EU Filings
Y-mAbs Therapeutics' omburtamab and Oncopeptides' melflufen are among 13 potential new treatments that have been submitted for pan-EU approval.
Amgen’s Sotorasib Updates Raise New Questions For KRAS Program
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.
EU Accelerated Assessment Tracker
Calliditas Therapeutics' lead product candidate Nefecon will be fast-tracked at the EMA once the marketing application is filed. Takeda and Bayer are hoping for the same success with aribavir and copanlisib respectively.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alpine Biosciences
- Biomira
- Oncothyreon, Inc.
- Cascadian Therapeutics, Inc.
- Seattle Genetics, Inc.